Home / Biotechnology / Cervical D

Cervical Dysplasia Diagnostic Market By Type (Diagnostic Test, Diagnostic Device) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Cervical carcinoma accounts for around 15% of all cancers diagnosed in women. Approximately 5 lakhs new cases of cervical cancer in women are observed annually, of which 80% occur in developing countries. Cervical dysplasia is a major health problem among women especially in developing countries with rising incidence of cancer. It is detected in women in their 20’s and peak incidence ranges between 25-35 years, while incidence of cervical cancer rises after 40 years. With rising awareness about cervical dysplasia, improvement in screening technology has led to early diagnosis and treatment to further avoid progression of disease. WHO along with national government are making efforts to build national cancer strategies based on the local need for early treatment and prevention of disease which would help in growth of cervical dysplasia diagnostic market.

The report titled “Cervical Dysplasia Diagnostic Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall cervical dysplasia diagnostic market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on diagnosis type and different geographies.

Geographically, the global cervical dysplasia diagnostic market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year. Further cross-sectional presented in terms of diagnosis type and constituent region/country level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cervical dysplasia diagnostic market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global cervical dysplasia diagnostic market. This report concludes with company profiles section that highlights major information about the key players engaged in global cervical dysplasia diagnostic market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the cervical dysplasia diagnostic market. The key players profiled in this report are Abbott Laboratories, Becton, Dickinson and company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline Plc, Helix BioPharma Corp., Hologic, Inc., Inovio Biomedical Corporation, Micromedic Technologies Ltd., OncoHealth Corporation, PDS Biotechnology Corporation, Photocure ASA, Quest Diagnostics, Inc., QIAGEN N.V. and others.

Cervical Dysplasia Diagnostic Market

Choose License Type
Published Date:  Sep 2017
Category:  Biotechnology
Report ID:   58678
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Connect With Us
24/7 Research Support